OPEN Foundation

Day: 26 May 2015

The positive effect on ketamine as a priming adjuvant in antidepressant treatment.

Abstract

Ketamine is an anesthetic with antidepressant properties. The rapid and lasting effect of ketamine observed in preclinical and clinical research makes it a promising therapeutic to improve current major depression (MD) treatment. Our work intended to evaluate whether the combined use of classic antidepressants (imipramine or fluoxetine) and ketamine would improve the antidepressant response. Using an animal model of depressive-like behavior, we show that the addition of ketamine to antidepressants anticipates the behavioral response and accelerates the neuroplastic events when compared with the use of antidepressants alone. In conclusion, our results suggest the need for a reappraisal of the current pharmacological treatment of MD.

Melo, A., Kokras, N., Dalla, C., Ferreira, C., Ventura-Silva, A. P., Sousa, N., & Pêgo, J. M. (2015). The positive effect on ketamine as a priming adjuvant in antidepressant treatment. Translational Psychiatry, 5(5), e573. https://dx.doi.org/10.1038/tp.2015.66
Link to full text

Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential

Abstract

Trials of physiologically safe and non-addictive drugs such as LSD are almost impossible, writes James J H Rucker, calling on the authorities to downgrade their unnecessarily restrictive class A, schedule 1 classification.

Rucker, J. J. (2015). Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. BMJ, 350, h2902. http://dx.doi.org/10.1136/bmj.h2902
Link to full text

Should Psychedelic Therapists Have Self-Experience? - Online Panel & Q&A - Jan 21